Tirzepatide lowers heart attack and cardiovascular event risk in adults with type 2 diabetes

Tirzepatide lowers heart attack and cardiovascular event risk in adults with type 2 diabetes

In a US cohort of 52,971 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide initiation was associated with a lower one-year risk of major adverse cardiovascular events than sitagliptin. The benefit was driven mainly by lower myocardial infarction and all-cause mortality hazards, although the authors cautioned that mortality findings may be influenced by residual confounding.

This Drug May Cut Heart Attack Risk in Type 2 Diabetes

People with type 2 diabetes are much more likely to develop heart disease than those without diabetes. High blood sugar can damage blood vessels over time, increasing the risk of heart attacks, strokes, and heart failure. Even when blood sugar is controlled, many patients remain at high risk of serious heart problems, so researchers continue […] The post This Drug May Cut Heart Attack Risk in Type 2 Diabetes appeared first on Knowridge Science R…

GLP-1 drug tirzepatide may cut risk by 33% - Health Care Today

Researchers continue to examine how GLP-1 medications may affect aspects of a person’s health outside of type 2 diabetes treatment and weight loss. Past studies show that GLP-1 drugs may help lower a person’s risk for cardiovascular disease. A new study found that adding tirzepatide to standard care for people with both type 2 diabetes and heart disease may help lower their risk for a major cardiovascular event. Now, a new study published in th…